Please provide your email address to receive an email when new articles are posted on . Up to 88% of sentinel lymph node biopsies (SNLB) return with a negative result. The DecisionDx-Melanoma test, ...
Testing a key lymph node in patients with the most dangerous form of skin cancer is the best approach to determine if the cancer has spread, new late-stage clinical research indicates. The test could ...
Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines’ 5% threshold to ...
ROCHESTER, Minn. — A genomic test co-developed by Mayo Clinic and SkylineDx can identify whether people with melanoma are at low or high risk for cancer in their lymph nodes — a finding that could ...
TAMPA, Fla. (Oct. 22, 2025) — A large multicenter clinical trial published in JAMA Surgery shows that a gene expression profile–based test can reliably identify melanoma patients who have a low risk ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from its prospective ...
Colon cancer treatment is personalized based on stage, overall health and tumor characteristics. Early detection and accurate ...
The National Institute for Health and Care Excellence has recommended a new test for surgeons to use during operations to discover if breast cancer has spread. The test - the RD-100i OSNA system ...
The committee considered the heterogeneity and uncertainty in the studies. The committee heard from the clinical specialists on the committee that histopathology practices can vary between hospitals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback